来自轻链氨基粉症治疗方法的心血管毒性
Paolo Morfino1, Alberto Aimo1,2, Vincenzo Castiglione1,2
1Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
Frontiers in cardiovascular medicine
|July 21, 2023
概括
粉样蛋白轻链 (AL) 粉样蛋白是一种影响器官,特别是心脏的血细胞疾病. 管理这种情况需要了解心脏瘤学,以防止治疗引起的心血管毒性.
科学领域:
- 血液学 血液学 血液学
- 心脏病学 心脏病学
- 在瘤学瘤学.
背景情况:
- 粉样蛋白轻链 (AL) 粉样蛋白病源于血细胞克隆产生错误折叠的轻链.
- 心脏干扰是常见的,导致限制性心肌病和不良预后.
- 治疗的目标是血细胞克隆,从多发性骨髓瘤疗法中调整出来.
研究的目的:
- 为了突出AL氨基粉症的复杂管理.
- 为了强调血液学治疗的心脏瘤学影响.
- 引导未来的预防策略研究和理解与治疗相关的心血管损伤.
主要方法:
- 对AL氨基粉症的当前治疗方法的审查.
- 分析多器官参与和对心血管毒性的敏感性.
- 在管理AL粉样化症患者心脏瘤学考虑的讨论.
主要成果:
- 由于涉及多个器官,AL氨基粉症需要综合管理.
- 血液学治疗带有心血管毒性的风险.
- 患有AL Amyloidosis的患者特别容易受到这些毒性的影响.
结论:
- 管理AL Amyloidosis需要对心脏瘤学的深刻理解.
- 未来的研究应该优先考虑初级和二级心血管预防策略.
- 研究治疗诱导的心血管损伤的生物化学基础对于缓解至关重要.
相关概念视频
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Cardiomyopathy V: Interprofessional Care
17
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
17
Heart Failure Drugs: Inotropic Agents
628
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
628
Chronic Kidney Disease II: Clinical Manifestations
34
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
34
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11


